GSEP
ALNY icon

Golden State Equity Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Golden State Equity Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$64.2K Buy
+194
New +$66K ﹤0.01% 834
2024
Q4 		– Sell
-23
Closed -$6.33K – 452
2024
Q3 		$6.33K Buy
+23
New +$5.99K ﹤0.01% 626

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Golden State Equity Partners's ALNY Position: Q1 2026 in Review

Golden State Equity Partners opened a new position in Alnylam Pharmaceuticals (ALNY) in Q1 2026: 194 shares worth $64.2K. The stake represents ﹤0.01% of the portfolio and ranks #834 among its holdings. This is a return to the name: Golden State Equity Partners previously reported a position in ALNY as recently as Q3 2024.

Golden State Equity Partners first reported a position in ALNY in Q3 2024 and has held it in 2 quarters since. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Golden State Equity Partners held 194 shares of Alnylam Pharmaceuticals worth $64.2K as of Q1 2026.
  • Alnylam Pharmaceuticals was a new Golden State Equity Partners position in Q1 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Golden State Equity Partners's portfolio in Q1 2026, its #834 holding.
  • Golden State Equity Partners first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 2 quarters since.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Golden State Equity Partners's 13F filing for Q1 2026, filed 28 Apr 2026.